BioCentury
ARTICLE | Clinical News

RTX resiniferatoxin: Expanded Phase II studies

July 12, 1999 7:00 AM UTC

Afferon Corp., Wayne, Penn. Product: RTX resiniferatoxin Business: Urological, Neurological Therapeutic category: Neurotransmission Target: Peripheral sensory neurons Description: Neuronal desensitizi...